Oxford Biomedica builds momentum with CDMO strategy shift
The Business Magazine - 12-Aug-2024Oxford Biomedica expects strong 2024 revenues after streamlining and focusing on gene therapy
Join the club for FREE to access the whole archive and other member benefits.
Gene and cell therapy company specialising in the development of gene-based medicines
Oxford BioMedica is a pioneer of gene and cell therapy, with a leading industry position in lentiviral vector and cell therapy research, development and manufacture. Gene therapy is the treatment of disease by delivering therapeutic DNA into a patient’s cells. This can be either in vivo or ex vivo, the latter encompassing the field of cell therapy whereby genetically modified cells are put back into the body. Their pipeline of seven gene and cell therapy therapy products addresses diseases for which there is currently no treatment or that are inadequately treated today, including ocular and central nervous system disorders. Their product candidates have the potential to transform treatment landscapes. Their strategy is to develop their product candidates to their next value inflection points whilst continuing to build OXB Solutions into a valuable revenue-generating manufacturing and development services business.
NOTE: rebranded as OXB in 2024
Visit website: https://www.oxfordbiomedica.co.uk/
Details last updated 08-May-2025
Oxford Biomedica expects strong 2024 revenues after streamlining and focusing on gene therapy